R

Rentoceratib

Product

by Insilico Medicine

Heard in 1 episode across 1 show since Sep 2026

Rentoceratib is an investigational small-molecule medicine being developed for idiopathic pulmonary fibrosis (IPF). Public search results associate it with Insilico Medicine and describe it as a generative-AI-discovered candidate targeting TNIK; it is not an approved marketed product based on the available information.

Episodes

1
across 1 show

First heard

Sep 2026

Expert statements

2
2 positive

Episodes per month

Public PodLume episodes featuring it, over the last year.

Show the data
MonthEpisodes
Nov 20250
Dec 20250
Jan 20260
Feb 20260
Mar 20260
Apr 20260
May 20260
Jun 20260
Jul 20260
Aug 20260
Sep 20261
Oct 20260

What experts have said about Rentoceratib

2 statements · 2 positive

  1. Peter H. DiamandisPositiveSep 28, 2026· Moonshots with Peter Diamandis

    Insilico’s rentoceratib advanced to Phase 3 trials for idiopathic pulmonary fibrosis.

    “rentoceratib has advanced to phase 3 trials in idiopathic pulmonary fibrosis”

    Listen at 2:10:59

    Open the episode · Should we slow down AI progress? | MOONSHOTS #288
  2. Alexander Wissner-GrossPositiveSep 28, 2026· Moonshots with Peter Diamandis

    Insilico’s Phase 2a study showed three to four years of biological age reversal after four weeks.

    “at week 4, they saw, according to these proteomic aging clocks, 3 to 4 years of biological age reversal.”

    Listen at 2:13:19

    Open the episode · Should we slow down AI progress? | MOONSHOTS #288
Filter the statements →

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

1 episode featuring Rentoceratib, newest first

Rentoceratib · PodLume